123P IMpower010: Exploratory overall survival (OS) with adjuvant atezolizumab (atezo) vs best supportive care (BSC) in stage II-IIIA NSCLC with high PD-L1 expression. (December 2022) - Rittmeyer, A.; Felip, E.; Altorki, N.K.; Vallieres, E.; Zhou, C.; Martinez-Marti, A.; Csoszi, T.; Reck, M.; Teixeira, M.E.; Deng, Y.; Huang, M.; McNally, V.A.; et al.